红花黄色素联合磷酸肌酸治疗缺血性心肌病的临床效果

Clinical Effect of Saffower Yellow Combined with Phosphocreatine on Ischemic Cardiomyopathy

目的探讨红花黄色素联合磷酸肌酸治疗缺血性心肌病的临床效果。方法将80例缺血性心肌病(ICM)患者按治疗用药不同分为2组:对照组38例按常规治疗;研究组42例在常规治疗基础上给予红花黄色素联合磷酸肌酸治疗。比较2组的临床疗效及治疗前后心功能指标[包括左心室射血分数(LVEF)、收缩末期内径(LVSD)、左心室舒张末期内径(LVDD)等]变化情况。结果研究组治疗总有效率显著高于对照组(92.9%比81.6%,χ~2=5.729、P<0.05);2组治疗后LVEF值均较治疗前显著升高(P<0.05),LVDD、LVSD值均较治疗前显著降低(P<0.05),且研究组改善情况显著优于对照组(P<0.05)。结论临床对ICM患者使用红花黄色素联合磷酸肌酸治疗,能有效改善患者心功能,避免患者心室重构,治疗效果良好。

Objective To investigate the clinical effect of saffower yellow combined with phosphocreatine on ischemic cardiomyopathy(ICM). Methods Eighty ICM patients were given conventional therapy alone(control group, n =38) or in combination with saffower yellow and phosphocreatine(study group, n =42).Left ventricular ejection fraction(LVEF),left ventricular end-systolic diameter(LVSD) and left ventricular end-diastolic diameter(LVDD) were measured before and after treatment.Clinical efficacy was compared between the two groups. Results The total effective rate in study group was higher than that in control group(92.9% vs 81.6%,χ^ 2 = 5.729 , P <0.05).After treatment,the LVEF increased but the LVDD and LVSD decreased in both groups( P <0.05).Furthermore,the improve in cardiac parameters in study group was more obvious than that in control group( P <0.05). Conclusion Saffower yellow combined with phosphocreatine can effectively improve cardiac function and avoid ventricular remodeling in ICM patients.